Peter J Schmidt

List of Publications by Year
in descending order

73 papers	6,868 citations	81900 39 h-index	88630 70 g-index
74 all docs	74 docs citations	74 times ranked	5050 citing authors

#	Article	IF	Citations
1	Subgenual cingulate resting regional cerebral blood flow in premenstrual dysphoric disorder: differential regulation by ovarian steroids and preliminary evidence for an association with expression of ESC/E(Z) complex genes. Translational Psychiatry, 2021, 11, 206.	4.8	4
2	Altered estradiol-dependent cellular Ca2+ homeostasis and endoplasmic reticulum stress response in Premenstrual Dysphoric Disorder. Molecular Psychiatry, 2021, 26, 6963-6974.	7.9	11
3	The Cortisol and ACTH Response to Dex/CRH Testing in Women With and Without Perimenopausal Depression. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3007-3018.	3.6	5
4	The NIMH Intramural Longitudinal Study of the Endocrine and Neurobiological Events Accompanying Puberty: Protocol and rationale for methods and measures. NeuroImage, 2021, 234, 117970.	4.2	6
5	The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression. Menopause, 2021, 28, 369-383.	2.0	12
6	Epigenetic intersection of BDNF Val66Met genotype with premenstrual dysphoric disorder transcriptome in a cross-species model of estradiol add-back. Molecular Psychiatry, 2020, 25, 572-583.	7.9	13
7	Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study. Archives of Women's Mental Health, 2020, 23, 401-412.	2.6	12
8	In vitro model of perimenopausal depression implicates steroid metabolic and proinflammatory genes. Molecular Psychiatry, 2020, 26, 3266-3276.	7.9	7
9	Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology, 2019, 44, 111-128.	5.4	174
10	Evaluation of incidental pelvic fluid in relation to physiological changes in healthy pubescent children using pelvic magnetic resonance imaging. Pediatric Radiology, 2019, 49, 784-790.	2.0	1
11	Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition. JAMA Psychiatry, 2018, 75, 149.	11.0	140
12	Progesterone and plasma metabolites in women with and in those without premenstrual dysphoric disorder. Depression and Anxiety, 2018, 35, 1168-1177.	4.1	5
13	The role of ovarian steroids in affective disorders. Current Opinion in Behavioral Sciences, 2018, 23, 103-112.	3.9	14
14	Is there a role for reproductive steroids in the etiology and treatment of affective disorders?. Dialogues in Clinical Neuroscience, 2018, 20, 187-196.	3.7	25
15	Depression during the menopause transition: impact on quality of life, social adjustment, and disability. Archives of Women's Mental Health, 2017, 20, 273-282.	2.6	38
16	Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. American Journal of Psychiatry, 2017, 174, 980-989.	7.2	123
17	Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry,the, 2017, 4, 477-485.	7.4	199
18	Perimenopausal depression and early menopause: cause or consequence?. Menopause, 2017, 24, 1333-1335.	2.0	5

#	Article	IF	Citations
19	Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Depression and Anxiety, 2017, 34, 908-917.	4.1	20
20	Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Archives of Women's Mental Health, 2016, 19, 953-958.	2.6	68
21	Reproductive Steroid Regulation of Mood and Behavior. , 2016, 6, 1135-1160.		129
22	Sex differences in visuospatial abilities persist during induced hypogonadism. Neuropsychologia, 2016, 81, 219-229.	1.6	14
23	5Î±-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology, 2016, 41, 1093-1102.	5.4	107
24	EFFICACY OF ESTRADIOL IN PERIMENOPAUSAL DEPRESSION: SO MUCH PROMISE AND SO FEW ANSWERS. Depression and Anxiety, 2015, 32, 539-549.	4.1	64
25	Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression. JAMA Psychiatry, 2015, 72, 714.	11.0	155
26	DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEAâ€™s antidepressant action. Psychopharmacology, 2015, 232, 3375-3383.	3.1	14
27	Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause, 2014, 21, 952-961.	2.0	24
28	Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback. Archives of Women's Mental Health, 2013, 16, 47-58.	2.6	22
29	Effects of Pharmacologically Induced Hypogonadism on Mood and Behavior in Healthy Young Women. American Journal of Psychiatry, 2013, 170, 426-433.	7.2	24
30	Abnormalities of Dorsolateral Prefrontal Function in Women With Premenstrual Dysphoric Disorder: A Multimodal Neuroimaging Study. American Journal of Psychiatry, 2013, 170, 305-314.	7.2	84
31	ACTH and Cortisol Response to Dex/CRH Testing in Women with and without Premenstrual Dysphoria during GnRH Agonist-Induced Hypogonadism and Ovarian Steroid Replacement. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1887-1896.	3.6	22
32	Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. American Journal of Psychiatry, 2012, 169, 465-475.	7.2	247
33	Summary of the National Institute on Aging-Sponsored Conference on Depressive Symptoms and Cognitive Complaints in the Menopausal Transition. Focus (American Psychiatric Publishing), 2012, 10, 102-110.	0.8	0
34	RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER. Depression and Anxiety, 2012, 29, 531-540.	4.1	52
35	Depression in Women with Spontaneous 46, XX Primary Ovarian Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E278-E287.	3.6	78
36	Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause, 2010, 17, 815-822.	2.0	90

#	Article	IF	Citations
37	Reproductive Aging, Sex Steroids, and Mood Disorders. Harvard Review of Psychiatry, 2009, 17, 87-102.	2.1	41
38	Pharmacologically Induced Hypogonadism and Sexual Function in Healthy Young Women and Men. Neuropsychopharmacology, 2009, 34, 565-576.	5.4	44
39	Frontiers proposal. National Institute on Aging â€œbench to bedside: estrogen as a case studyâ€• Age, 2009, 31, 199-210.	3.0	25
40	Sex Hormones and Mood in the Perimenopause. Annals of the New York Academy of Sciences, 2009, 1179, 70-85.	3.8	123
41	Estrogen and progestogen use in postmenopausal women. Menopause, 2008, 15, 584-602.	2.0	211
42	A Cross-Sectional Evaluation of Perimenopausal Depression. Journal of Clinical Psychiatry, 2008, 69, 973-980.	2.2	57
43	Why study reproductive neuroscience? A clinical perspective. Journal of Clinical Psychiatry, 2008, 69, 972.	2.2	0
44	Menstrual cycle phase modulates reward-related neural function in women. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2465-2470.	7.1	474
45	The menopause transition: the next neuroendocrine frontier. Expert Review of Neurotherapeutics, 2007, 7, S7-S10.	2.8	11
46	Estrogens and Depression in Women. , 2007, , 307-320.		1
47	Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women. Journal of Neuroscience, 2006, 26, 10332-10348.	3.6	297
48	Adult women with Turner syndrome: A systematic evaluation of current and past psychiatric illness, social functioning, and self-esteem. International Congress Series, 2006, 1298, 100-107.	0.2	11
49	Monoamines and Neurosteroids in Sexual Function During Induced Hypogonadism in Healthy Men. Archives of General Psychiatry, 2006, 63, 450.	12.3	14
50	Gonadal steroid regulation of mood: The lessons of premenstrual syndromeâ˜†. Frontiers in Neuroendocrinology, 2006, 27, 210-216.	5.2	107
51	Premenstrual Symptoms and Perimenopausal Depression. American Journal of Psychiatry, 2006, 163, 133-137.	7.2	67
52	Reproductive ageing, sex steroids and depression. The Journal of the British Menopause Society, 2006, 12, 178-185.	1.3	18
53	Shyness, Social Anxiety, and Impaired Self-esteem in Turner Syndrome and Premature Ovarian Failure. JAMA - Journal of the American Medical Association, 2006, 295, 1373.	7.4	138
54	Depression, the Perimenopause, and Estrogen Therapy. Annals of the New York Academy of Sciences, 2005, 1052, 27-40.	3.8	44

#	Article	IF	Citations
55	Dehydroepiandrosterone Monotherapy in Midlife-Onset Major and Minor Depression. Archives of General Psychiatry, 2005, 62, 154.	12.3	221
56	Mood, depression, and reproductive hormones in the menopausal transition. American Journal of Medicine, 2005, 118, 54-58.	1.5	84
57	A Longitudinal Evaluation of the Relationship Between Reproductive Status and Mood in Perimenopausal Women. American Journal of Psychiatry, 2004, 161, 2238-2244.	7.2	211
58	Current and lifetime psychiatric illness in women with Turner syndrome. Gynecological Endocrinology, 2004, 19, 313-319.	1.7	68
59	The Effects of Pharmacologically Induced Hypogonadism on Mood in HealthyMen. Archives of General Psychiatry, 2004, 61, 997.	12.3	90
60	Current and lifetime psychiatric illness in women with Turner syndrome. Gynecological Endocrinology, 2004, 19, 313-9.	1.7	18
61	Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. Journal of Psychiatric Research, 2003, 37, 75-83.	3.1	54
62	Differential Menstrual Cycle Regulation of Hypothalamic-Pituitary-Adrenal Axis in Women with Premenstrual Syndrome and Controls. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3057-3063.	3.6	149
63	Concordant Restoration of Ovarian Function and Mood in Perimenopausal Depression. American Journal of Psychiatry, 2003, 160, 1842-1846.	7.2	51
64	The Effects of Gender and Gonadal Steroids on the Neuroendocrine and Temperature Response to m-Chlorophenylpiperazine in Leuprolide-induced Hypogonadism in Women and Men. Neuropsychopharmacology, 2002, 27, 800-812.	5.4	12
65	Reproductive hormonal treatments for mood disorders in women. Dialogues in Clinical Neuroscience, 2002, 4, 211-223.	3.7	5
66	Estrogen replacement in perimenopause-related depression: A preliminary report. American Journal of Obstetrics and Gynecology, 2000, 183, 414-420.	1.3	539
67	Dehydroepiandrosterone treatment of midlife dysthymiaâˆ—â€”See accompanying Editorial, in this issue.. Biological Psychiatry, 1999, 45, 1533-1541.	1.3	185
68	Estrogenâ€“serotonin interactions: implications for affective regulation. Biological Psychiatry, 1998, 44, 839-850.	1.3	444
69	Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome. New England Journal of Medicine, 1998, 338, 209-216.	27.0	618
70	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3203-3207.	3.6	39
71	Effect of Menstrual Cycle Phase on Neuroendocrine and Behavioral Responses to the Serotonin Agonistm-Chlorophenylpiperazine in Women with Premenstrual Syndrome and Controls1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1220-1228.	3.6	74
72	Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome. New England Journal of Medicine, 1991, 324, 1174-1179.	27.0	173

#	Article	IF	Citations
73	Hypothalamic-Pituitary-Adrenal Function in Patients with the Premenstrual Syndrome. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1158-1162.	3.6	85